超声心动图改善无已知心脏病1型糖尿病人群主要不良心血管事件的预测:Thousand & 1研究
该前瞻性队列纳入1093例无已知心脏病的1型糖尿病患者,随访7.5年,145例(13.3%)发生MACE。超声心动图参数(LVEF<45%、GLS受损、E/e'异常)独立预测MACE,且在Steno T1D风险引擎基础上显著改善风险预测(C统计量0.791 vs 0.780,NRI 52%)。
要点
- LVEF<45%者MACE风险显著增高(HR 3.93,95%CI 1.91-8.08)。
- GLS受损独立预测MACE(HR 1.65,95%CI 1.17-2.34)。
- 超声参数加入临床风险引擎可改善风险分层(NRI 52%)。
核心结论
- 在无已知心脏病的1型糖尿病患者中,超声心动图可独立预测MACE,并在指南推荐的临床风险因素之上显著改善风险预测。
研究设计与样本
- 前瞻性队列研究,从门诊招募无已知心脏病的1型糖尿病患者,通过丹麦国家登记系统随访。
- 共纳入1093例,中位年龄50.2(39.2-60.3)岁,HbA1c 65(56-74)mmol/mol,53%为男性,平均BMI 25.5(3.9)kg/m2,平均糖尿病病程25.8(14.6)年。
主要发现
- 随访7.5年间,145例(13.3%)发生MACE。
- LVEF<45%(n=18) vs ≥45%(n=1075):HR 3.93(95%CI 1.91-8.08),p<0.001。
- GLS受损(n=263):HR 1.65(95%CI 1.17-2.34),p=0.005。
- E/e'<8(n=723) vs E/e' 8-12(n=285):HR 1.59(95%CI 1.04-2.42),p=0.031;E/e'<8 vs E/e'≥12(n=85):HR 2.30(95%CI 1.33-3.97),p=0.003。
- 在LVEF保留者(n=1075)中,GLS受损HR 1.49(95%CI 1.04-2.15),p=0.032;E/e'<8 vs 8-12 HR 1.61(95%CI 1.04-2.49),p=0.033;E/e'<8 vs ≥12 HR 2.49(95%CI 1.41-4.37),p=0.001。
关键数值与推荐
- 超声心动图变量加入Steno T1D风险引擎后,Harrell's C统计量从0.780(95%CI 0.746-0.815)提升至0.791(95%CI 0.757-0.824),p=0.027。
- 净重分类指数(NRI)为52%,p<0.001。
临床怎么用
- 对于无已知心脏病的1型糖尿病患者,可考虑将超声心动图(包括LVEF、GLS、E/e')纳入风险评估,以改善MACE风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Cardiovascular disease is the most common comorbidity in type 1 diabetes. However, current guidelines do not include routine assessment of myocardial function. We investigated whether echocardiography provides incremental prognostic information in individuals with type 1 diabetes without known heart disease. METHODS: A prospective cohort of individuals with type 1 diabetes without known heart disease was recruited from the outpatient clinic. Follow-up was performed through Danish national registers. The association of echocardiography with major adverse cardiovascular events (MACE) and the incremental prognostic value when added to the clinical Steno T1D Risk Engine were examined. RESULTS: A total of 1093 individuals were included: median (interquartile range) age 50.2 (39.2-60.3) years and HbA1c 65 (56-74) mmol/mol; 53% men; and mean (SD) BMI 25.5 (3.9) kg/m2 and diabetes duration 25.8 (14.6) years. During 7.5 years of follow-up, 145 (13.3%) experienced MACE. Echocardiography significantly and independently predicted MACE: left ventricular ejection fraction (LVEF) <45% (n = 18) vs ≥45% (n = 1075), HR (95% CI) 3.93 (1.91, 8.08), p < 0.001; impaired global longitudinal strain (GLS), 1.65 (1.17, 2.34) (n = 263), p = 0.005; diastolic mitral early velocity (E)/early diastolic tissue Doppler velocity (e') <8 (n = 723) vs E/e' 8-12 (n = 285), 1.59 (1.04, 2.42), p = 0.031; and E/e' <8 vs E/e' ≥12 (n = 85), 2.30 (1.33, 3.97), p = 0.003. In individuals with preserved LVEF (n = 1075), estimates for impaired GLS were 1.49 (1.04, 2.15), p = 0.032; E/e' <8 vs E/e' 8-12, 1.61 (1.04, 2.49), p = 0.033; and E/e' <8 vs E/e' ≥12, 2.49 (1.41, 4.37), p = 0.001. Adding echocardiographic variables to the Steno T1D Risk Engine significantly improved risk prediction: Harrell's C statistic, 0.791 (0.757, 0.824) vs 0.780 (0.746, 0.815), p = 0.027; and net reclassification index, 52%, p < 0.001. CONCLUSIONS/INTERPRETATION: In individuals with type 1 diabetes without known heart disease, echocardiography significantly improves risk prediction over and above guideline-recommended clinical risk factors alone and could have a role in clinical care.
引用
- Jensen MT, Sogaard P, Gustafsson I, et al. Echocardiography improves prediction of major adverse cardiovascular events in a population with type 1 diabetes and without known heart disease: the Thousand & 1 Study. Diabetologia. 2019. PMID: 31664481. doi:10.1007/s00125-019-05009-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。